In his role, Dr. Mayer will work closely with Ipsen\u2019s Business Development team to assess and execute on in-licensing or out-licensing opportunities and build internal expertise accordingly. He will also contribute to the overall management and strategic leadership of the company as a member of the Executive Leadership team. Recognized as an exceptional team leader, Dr. Mayer will be responsible for building a culture centered on collaboration, agility and partnership. By doing so, he will fulfill the company\u2019s vision as a leading global biopharmaceutical company focused on innovation and Specialty Care.<\/p>\n
Prior to joining Ipsen, Dr. Mayer was Senior Vice President, Chief Medical Officer and Head of Research and Development, Neuroscience Division, Shire Pharmaceuticals. Dr. Mayer has held several global leadership positions in clinical development and medical affairs with biopharmaceutical companies including EMD Serono, Pfizer and Bristol-Myers Squibb. He obtained his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School.<\/p>\n
About Ipsen<\/b> Ipsen\u2014Cautionary Note Regarding Forward-Looking Statements<\/b> For further information:<\/u><\/b><\/p>\n <\/p>\n \u00a0<\/b><\/p>\n Financial Community<\/b> Fanny Allaire<\/b> \u00a0<\/p>\n \u00a0<\/p>\n Myriam Koutchinsky<\/b> \n Attachment<\/strong>\n<\/p>\n
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas \u2013 Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over \u20ac2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen\u2019s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit\u00a0www.ipsen.com<\/u><\/b><\/a><\/p>\n
The forward-looking statements, objectives and targets contained herein are based on the Group\u2019s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group\u2019s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words \u201cbelieves\u201d, \u201canticipates\u201d and \u201cexpects\u201d and similar expressions are intended to identify forward-looking statements, including the Group\u2019s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group\u2019s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group\u2019s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group\u2019s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group\u2019s business is subject to the risk factors outlined in its registration documents filed with the French Autorit\u00e9 des March\u00e9s Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group\u2019s 2018 Registration Document available on its website (www.ipsen.com<\/u><\/b><\/a>).<\/p>\n\n
\n \u00a0<\/td>\n \u00a0<\/td>\n \u00a0<\/td>\n<\/tr>\n \n \u00a0<\/td>\n \u00a0<\/td>\n \u00a0<\/td>\n<\/tr>\n \n Media<\/b>
Christian Marcoux<\/b>
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Christian.marcoux@ipsen.com<\/u><\/b><\/a><\/p>\n
Eugenia Litz<\/b>
Vice President, Investor Relations
+44 (0) 1753 627721
eugenia.litz@ipsen.com<\/u><\/b><\/a> <\/td>\n \u00a0<\/p>\n
Director, Ipsen France Hub, Global Communications
+33 (0) 1 58 33 58 96
Fanny.allaire@ipsen.com<\/u><\/p>\n
Investor Relations Manager
+33 (0)1 58 33 51 04
myriam.koutchinsky@ipsen.com<\/u><\/b><\/a> <\/td>\n<\/tr>\n<\/table>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1763,149],"tags":[],"class_list":["post-36223","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease","category-pressrelease","entry"],"acf":[],"yoast_head":"\n